Third Harmonic Bio, Inc. (THRD)
| Market Cap | 435.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.48M |
| Shares Out | 39.73M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 477,595 |
| Open | 11.38 |
| Previous Close | 11.43 |
| Day's Range | 10.80 - 11.50 |
| 52-Week Range | 3.75 - 11.60 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 7.00 (-36.19%) |
| Earnings Date | Nov 9, 2023 |
About THRD
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for THRD stock is "Hold" and the 12-month stock price forecast is $7.0.
News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The investigation s...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H'24
Third Harmonic Bio Announces Leadership Changes
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distrib...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Third Harmonic Bio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile
Third Harmonic Bio Announces First Quarter 2023 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated ...
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated ...
Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Third Harmonic's stock falls 75% after discontinuing clinical trial
Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common infl...
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and i...
Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Successfully Completed Upsized Initial Public Offering Providing Funding Through 2025
Third Harmonic Scores Most Successful Biotech IPO in Months
A partner in a large Cambridge, Massachusetts-based venture capital firm is confident that investors' appetite for biotech startups will begin to pick up in the fall.
Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for t...
Third Harmonic Bio stock opens more than 20% above IPO price
Third Harmonic Bio Inc. THRD, +22.50% received a warm Wall Street welcome Thursday, as the biotechnology company's stock opened 20.6% above the initial public offering price. The company, which specia...
Third Harmonic Bio prices upsized IPO at $17 a share, midpoint of range
Third Harmonic Bio Inc. THRD, -58.40% , a biotech specializing in allergic and inflammatory diseases, priced its initial public offering late Wednesday at $17 a share the midpoint of its $16 to $18 pr...
Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for t...